News &amp; Updates

Young women are more likely to develop stroke than young men, according to a study, highlighting the importance of sex-mediated risk factors.

Sex differences seen in stroke incidence among younger adults

Product Highlight - Tozene

Flucytosine 500 mg Capsule

Product Highlight - Tozene

Product Highlight - Ferinject

Ferric carboxymaltose 50 mg iron/mL Solution for Injection/Infusion

Product Highlight - Ferinject

Product Highlight - Amgevita

Adalimumab 50 mg/mL Solution for Injection

Product Highlight - Amgevita

Liver enzyme elevations in COVID-19 secondary to other conditions

The elevations in liver enzymes that occur in patients with COVID-19 may be due to other conditions and not as a direct result of COVID-19, according to a poster presented at the AASLD 2020 Liver Meeting.

Liver enzyme elevations in COVID-19 secondary to other conditions

Restful sleep improves mental health, grades of college students

College students who have frequent restful sleeps appear to have lower depressive symptoms and a better grade point average (GPA), a recent study has shown.

Restful sleep improves mental health, grades of college students

Oral as good as IV antibiotics for ridding P aeruginosa in cystic fibrosis

Intravenous (IV) antibiotics are no better than oral antibiotics when it comes to eradicating Pseudomonas (P.) aeruginosa in children and adults with cystic fibrosis, yet are more costly than the latter, reveals the TORPEDO-CF study.

Oral as good as IV antibiotics for ridding P aeruginosa in cystic fibrosis

High-dose fasinumab beneficial to chronic low back pain patients with peripheral OA

Fasinumab at the highest doses holds promise in the management of chronic low back pain (CLBP), improving both pain and function regardless of the presence of peripheral osteoarthritis (OA), according to the results of a phase II/III study.

High-dose fasinumab beneficial to chronic low back pain patients with peripheral OA

Pazopanib confers survival benefits in advanced soft tissue sarcoma

Treatment with pazopanib provides clinical benefit in patients with advanced soft tissue sarcoma in a Turkish cohort, with an acceptable safety profile, according to a study.

Pazopanib confers survival benefits in advanced soft tissue sarcoma

Baricitinib + topical therapy: Better for moderate-to-severe atopic dermatitis?

The oral Janus kinase (JAK) 1/2 inhibitor baricitinib showed potential as an add-on to background topical corticosteroids (TCS) for treating moderate-to-severe atopic dermatitis (AD) that does not respond well to TCS alone, the phase III BREEZE-AD7 trial suggests.

Baricitinib + topical therapy: Better for moderate-to-severe atopic dermatitis?